HUMIRA delivers 9th year of double-digit growth in 2012; forecasting low double-digit growth in 2013 Advances 11 Phase III programs; HCV Phase III trials underway and on track for early 2015 launch Provides full-year 2013 adjusted EPS guidance of $3.03 to $3.13 ($2.66 to $2.76 on a GAAP basis)

- Abbott will host a conference call to discuss Q4 and full-year 2012 business results and 2013 outlook on Jan. 23, 2013 ­- AbbVie will host a conference call to discuss 2012 business results and 2013 outlook on Jan. 30, 2013 ABBOTT PARK, Ill. and NORTH CHICAGO, Ill. , Jan.

NORTH CHICAGO, Ill. , Jan. 4, 2013 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV), a global biopharmaceutical company, today declared the Company's first quarterly cash dividend of $0.40 per share.  The cash dividend is payable Feb.